This study is looking at a treatment combination of TATE (Trans-arterial Tirapazamine Embolization) and pembrolizumab (a checkpoint inhibitor, which helps your immune system fight cancer) for people with metastatic colorectal cancer (mCRC) or non-small cell lung cancer (NSCLC) that has spread to the liver. You might be eligible if your cancer has specific characteristics, like not having certain mutations (changes in your genes) such as EGFR or AKT. For mCRC, the study will compare this new combination to standard treatments like TAS-102 or regorafenib, focusing on how long people live (Overall Survival). For NSCLC, everyone will receive TATE and pembrolizumab, and researchers will measure how much the tumors shrink (Overall Response Rate).

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It aims to enroll 110 participants.

What's involved

Pembrolizumab is given intravenously (IV) every 3 or 6 weeks for up to 2 years or until your cancer progresses. If you are in the mCRC arm, you might take TAS-102 or regorafenib pills on a specific schedule.

Compensation

Not stated in the trial record.

Follow-up

Overall survival for mCRC will be measured at 24 months. Overall response rate for NSCLC will be measured within 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.